Category Ranking
98%
Total Visits
921
Avg Visit Duration
2 minutes
Citations
20
Article Abstract
Background: Transplant centers exclude patients from the waiting list with reduced left ventricular ejection fraction (LVEF). It is unclear whether renal transplantation (RT) is safe, will have different impacts on patients with ischemic/nonischemic reduced LVEF, and whether myocardial revascularization will influence prognosis.
Methods: Four hundred and sixty RT patients assessed for coronary artery disease (CAD) and with LVEF determined before and after RT were divided into four groups (Group 1: No CAD and normal LVEF [reference]; Group 2: CAD and normal LVEF; Group 3: No CAD and reduced LVEF [nonischemic cardiomyopathy]; Group 4: CAD and reduced LVEF [ischemic cardiomyopathy]) and followed until death.
Results: RT was associated with increased LVEF in patients with cardiomyopathy. Patients with ischemic cardiomyopathy had a reduced survival rate; coronary intervention and medical treatment had comparable effects on outcomes. However, LVEF or CAD did not influence outcomes.
Conclusions: RT can be performed safely in patients with ischemic and nonischemic reduced LVEF and is associated with substantial improvement in LVEF. Although the long-term outcomes were poorer in patients with ischemic disease, LVEF and CAD were not independent predictors of events or death after adjustments. Therefore, reduced LVEF, even in patients with CAD, should not hamper the indication for RT.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1111/ctr.70176 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Full Free-Breathing Cardiac MRI: Enhancing Efficiency and Image Quality in Clinical Practice.
J Cardiovasc Magn Reson
September 2025
Department of Magnetic Resonance Imaging, Fuwai Hospital and National Center for Cardiovascular Diseases, Peking Union Medical College and Chinese Academy of Medical Sciences, Beijing 100037, China; Key Laboratory of Cardiovascular Imaging, Chinese Academy of Medical Sciences, Beijing 100730, China.
Background: Conventional cardiac magnetic resonance (CMR) examinations require patients to repeatedly hold their breath, which can reduce examination efficiency and pose challenges for patients unable to do so. This study aimed to demonstrate the feasibility and effectiveness of a full free-breathing CMR protocol in clinical practice.
Methods: Patients prospectively enrolled in this study underwent a full free-breathing CMR exam on a 3T scanner between June 1 and June 30, 2024.
Background: At present, existing risk scores together with traditional biomarkers such as troponin and brain natriuretic peptide (BNP) are still unable to accurately predict cancer therapy-related cardiac dysfunction (CTRCD). MicroRNAs (miRNAs) have emerged as promising biomarkers for improved identification of high-risk patients; however, limited studies have been performed in patients with HER2-positive breast cancer.
Objectives: To investigate the predictive potential of six serum-derived circulating miRNAs for CTRCD occurrence in patients with early-stage HER2-positive breast cancer receiving trastuzumab (TTZ).
A novel treatment score (QUAD score) to promote treatment optimization in heart failure with a reduced ejection fraction.
ESC Heart Fail
September 2025
School of Cardiovascular and Metabolic Health, University of Glasgow, British Heart Foundation Glasgow Cardiovascular Research Centre, Glasgow, UK.
Aims: To help avoid therapeutic inertia, we developed a pragmatic treatment score (QUAD Score) for use in daily practice by healthcare professionals managing patients with a left ventricular ejection fraction (LVEF) < 50% and heart failure. We now investigate the association between achieved QUAD scores and 1 year outcomes.
Methods: This was a multicentre cohort study in consecutive patients with incident heart failure and LVEF <50%, who completed therapy titration between January 2021 and June 2023.
The CONDUCT-AF trial: Rationale and design of a prospective, randomized, multicentre study comparing conduction system and biventricular pacing in patients undergoing atrioventricular node ablation for heart failure with atrial fibrillation.
Eur J Heart Fail
September 2025
Cardiology Department, University Medical Centre Ljubljana, Ljubljana, Slovenia.
Aims: There is a lack of data from randomized clinical trials comparing treatment outcomes between conduction system pacing (CSP) modalities and biventricular pacing (BVP) in symptomatic patients with refractory atrial fibrillation (AF) scheduled for atrioventricular node ablation (AVNA). The CONDUCT-AF investigates whether CSP is non-inferior to BVP in improving left ventricular ejection fraction (LVEF) and clinical outcomes in heart failure (HF) patients with symptomatic AF undergoing AVNA.
Methods: This study is an investigator-initiated, prospective, randomized, multicentre clinical trial conducted across 10 European centres, enrolling 82 patients with symptomatic AF, HF with reduced LVEF, and narrow QRS.
Electroacupuncture Improves Myocardial Fibrosis in Association With Intestinal Flora and Metabolic Modulation in Mice.
Cardiol Res Pract
August 2025
School of Medicine, Xiamen University, Xiamen 361102, Fujian, China.
This study investigates the reparative effect of electroacupuncture on myocardial fibrosis (MF) in mice and explores its impact on intestinal flora and metabolism profile. This examines an investigation into the biological mechanisms underlying electroacupuncture's efficacy in treating MF in mice. Twenty-four male Kunming mice (27-34 g) were randomized into three groups: normal control (NC, = 8), MF model (MF, = 8), and electroacupuncture treatment (EA, = 8).
View Article and Find Full Text PDF